NASDAQ:KRYS Krystal Biotech (KRYS) Stock Price, News & Analysis $184.19 -1.87 (-1.01%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$181.36▼$187.1350-Day Range$174.70▼$213.6652-Week Range$93.95▼$219.34Volume92,811 shsAverage Volume355,202 shsMarket Capitalization$5.26 billionP/E Ratio98.50Dividend YieldN/APrice Target$194.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Krystal Biotech alerts: Email Address Krystal Biotech MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside5.7% Upside$194.75 Price TargetShort InterestBearish12.40% of Shares Sold ShortDividend StrengthN/ASustainability-0.87Upright™ Environmental ScoreNews Sentiment0.72Based on 3 Articles This WeekInsider TradingSelling Shares$4.39 M Sold Last QuarterProj. Earnings Growth133.55%From $3.13 to $7.31 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.37 out of 5 starsMedical Sector110th out of 910 stocksBiological Products, Except Diagnostic Industry14th out of 155 stocks 2.5 Analyst's Opinion Consensus RatingKrystal Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageKrystal Biotech has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Krystal Biotech's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted12.40% of the outstanding shares of Krystal Biotech have been sold short.Short Interest Ratio / Days to CoverKrystal Biotech has a short interest ratio ("days to cover") of 9.1.Change versus previous monthShort interest in Krystal Biotech has recently increased by 1.14%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldKrystal Biotech does not currently pay a dividend.Dividend GrowthKrystal Biotech does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreKrystal Biotech has received a 73.65% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Preclinical research services for physical health", "Clinical research services for deficiency diseases", and "Clinical research services for genetic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Krystal Biotech is -0.87. Previous Next 2.1 News and Social Media Coverage News SentimentKrystal Biotech has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Krystal Biotech this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for KRYS on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Krystal Biotech to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Krystal Biotech insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,394,000.00 in company stock.Percentage Held by Insiders14.10% of the stock of Krystal Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.29% of the stock of Krystal Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Krystal Biotech's insider trading history. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Krystal Biotech are expected to grow by 133.55% in the coming year, from $3.13 to $7.31 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Krystal Biotech is 98.50, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 127.87.Price to Earnings Ratio vs. SectorThe P/E ratio of Krystal Biotech is 98.50, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 115.64.Price to Book Value per Share RatioKrystal Biotech has a P/B Ratio of 6.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Krystal Biotech's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Golden CrestBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.>> Get Your FREE Wealth Protection Guide << About Krystal Biotech Stock (NASDAQ:KRYS)Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.Read More KRYS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KRYS Stock News HeadlinesSeptember 6 at 7:00 AM | globenewswire.comKrystal Biotech to Present at H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 3, 2024 | markets.businessinsider.comKrystal Biotech Buy Rating Affirmed with Raised Price Target Amid Positive Development and Expansion ProspectsSeptember 7, 2024 | Paradigm Press (Ad)Kamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… August 30, 2024 | markets.businessinsider.comKrystal Biotech (KRYS) Receives a Buy from TD CowenAugust 30, 2024 | americanbankingnews.comCantor Fitzgerald Reiterates "Overweight" Rating for Krystal Biotech (NASDAQ:KRYS)August 30, 2024 | americanbankingnews.comHC Wainwright Boosts Krystal Biotech (NASDAQ:KRYS) Price Target to $221.00August 30, 2024 | americanbankingnews.comFinancial Comparison: Krystal Biotech (NASDAQ:KRYS) vs. Innate Pharma (NASDAQ:IPHA)August 30, 2024 | americanbankingnews.comKrystal Biotech (NASDAQ:KRYS) Trading 2.7% Higher on Analyst UpgradeSeptember 7, 2024 | Paradigm Press (Ad)Kamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… August 29, 2024 | markets.businessinsider.comBuy Rating Affirmed for Krystal Biotech Following Promising KB301 Study ResultsAugust 29, 2024 | msn.comKrystal Biotech's Jeune reports promising phase 1 data on wrinkles drugAugust 29, 2024 | americanbankingnews.comKrystal Biotech, Inc. (NASDAQ:KRYS) Given Consensus Recommendation of "Moderate Buy" by BrokeragesAugust 29, 2024 | americanbankingnews.comKrystal Biotech (NASDAQ:KRYS) Trading Up 2.7% Following Analyst UpgradeAugust 16, 2024 | finance.yahoo.comKrystal Biotech's (NASDAQ:KRYS) Earnings Might Be Weaker Than You ThinkAugust 12, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Krystal Biotech (KRYS) and InflaRx (IFRX)August 9, 2024 | benzinga.comHere's How Much $1000 Invested In Krystal Biotech 5 Years Ago Would Be Worth TodayAugust 9, 2024 | seekingalpha.comKrystal Biotech, Inc. 2024 Q2 - Results - Earnings Call PresentationAugust 7, 2024 | msn.comCitigroup Downgrades Krystal Biotech (KRYS)See More Headlines Receive KRYS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Krystal Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/05/2024Today9/07/2024Next Earnings (Estimated)11/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KRYS CUSIPN/A CIK1711279 Webwww.krystalbio.com Phone(412) 586-5830FaxN/AEmployees210Year Founded2017Price Target and Rating Average Stock Price Target$194.75 High Stock Price Target$221.00 Low Stock Price Target$160.00 Potential Upside/Downside+3.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)$1.87 Trailing P/E Ratio98.50 Forward P/E Ratio58.85 P/E GrowthN/ANet Income$10.93 million Net Margins63.73% Pretax Margin65.20% Return on Equity1.99% Return on Assets1.87% Debt Debt-to-Equity RatioN/A Current Ratio9.50 Quick Ratio9.33 Sales & Book Value Annual Sales$166.23 million Price / Sales31.64 Cash FlowN/A Price / Cash FlowN/A Book Value$29.20 per share Price / Book6.31Miscellaneous Outstanding Shares28,558,000Free Float24,531,000Market Cap$5.26 billion OptionableOptionable Beta0.84 Social Links 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Krish S. Krishnan M.B.A. (Age 59)M.S., Founder, Chairman, President & CEO Comp: $1.07MMs. Suma M. Krishnan (Age 59)Founder, COO, President of R&D and Director Comp: $789.92kMs. Kathryn A. Romano (Age 42)Executive VP & Chief Accounting Officer Comp: $528.87kMr. John ThomasGeneral Counsel & Corporate SecretaryMr. John KarakkalVice President of North American Sales & MarketingMs. Christine WilsonHead of U.S. Sales and MarketingMr. Josh SuskinDirector of Human Resources & OperationsDr. Hubert C. Chen M.D. (Age 55)Senior Vice President of Clinical Development Mr. Laurent GouxSenior VP & GM of EuropeMr. Ram KamineniSenior Vice President of CMC & Technical OperationsMore ExecutivesKey CompetitorsBioCryst PharmaceuticalsNASDAQ:BCRXiTeos TherapeuticsNASDAQ:ITOSAlectorNASDAQ:ALECTaysha Gene TherapiesNASDAQ:TSHANantKwestNASDAQ:NKView All CompetitorsInsiders & InstitutionsTeachers Retirement System of The State of KentuckyBought 3,021 shares on 8/26/2024Ownership: 0.011%Nantahala Capital Management LLCBought 3,900 shares on 8/20/2024Ownership: 0.000%Driehaus Capital Management LLCBought 8,547 shares on 8/16/2024Ownership: 0.416%Creative PlanningBought 618 shares on 8/16/2024Ownership: 0.012%Algert Global LLCBought 1,853 shares on 8/16/2024Ownership: 0.006%View All Insider TransactionsView All Institutional Transactions KRYS Stock Analysis - Frequently Asked Questions How have KRYS shares performed this year? Krystal Biotech's stock was trading at $124.06 at the beginning of 2024. Since then, KRYS shares have increased by 48.5% and is now trading at $184.19. View the best growth stocks for 2024 here. How were Krystal Biotech's earnings last quarter? Krystal Biotech, Inc. (NASDAQ:KRYS) posted its quarterly earnings data on Monday, August, 5th. The company reported $0.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.50 by $0.03. The firm's quarterly revenue was up 70283900.0% on a year-over-year basis. When did Krystal Biotech IPO? Krystal Biotech (KRYS) raised $30 million in an initial public offering on Wednesday, September 20th 2017. The company issued 3,000,000 shares at $9.00-$11.00 per share. Ladenburg Thalmann served as the underwriter for the IPO. Who are Krystal Biotech's major shareholders? Krystal Biotech's top institutional investors include Avoro Capital Advisors LLC (8.52%), Dimensional Fund Advisors LP (2.03%), Hood River Capital Management LLC (1.82%) and Bank of New York Mellon Corp (0.68%). Insiders that own company stock include Krish S Krishnan, Suma Krishnan, Daniel Janney, Dino A Rossi, Kathryn Romano, Andrew C Orth and Julian S Gangolli. View institutional ownership trends. How do I buy shares of Krystal Biotech? Shares of KRYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Krystal Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Krystal Biotech investors own include Pfizer (PFE), Allena Pharmaceuticals (ALNA), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), VBI Vaccines (vbiv) and Verastem (VSTM). This page (NASDAQ:KRYS) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Krystal Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Krystal Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
